Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Systemic juvenile idiopathic arthritis (s-JIA) is clinically distinct from other types of JIA. It is typified by extraarticular features such as quotidian fevers, rash, splenomegaly, lymphadenopathy, laboratory abnormalities (including leukocytosis, thrombocytosis, anemia, hyperferritinemia, and elevated inflammatory markers), and a close association with the macrophage activation syndrome. Recent investigations have highlighted dysregulation of the innate immune system as the critical pathogenic driver of s-JIA. Key innate immune mediators of s-JIA are the macrophage-derived cytokines interleukin-1 (IL-1) and IL-6. Increased understanding of the roles of IL-1 and IL-6 in the pathogenesis of s-JIA has led to major changes in therapeutic options. Until recently, the most commonly used medications included corticosteroids, methotrexate, and tumor necrosis factor (TNF) inhibitors, which are incompletely effective in most cases. Newer biologic agents targeting IL-1 and IL-6 have proven very effective in treating s-JIA and in minimizing corticosteroid exposure. Here we review recent advances in the understanding of the pathogenesis of s-JIA and the recent clinical trials that have revolutionized the care of children with s-JIA.

Original languageEnglish (US)
Pages (from-to)176-183
Number of pages8
JournalPediatric Research
Volume75
Issue number1-2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Juvenile Arthritis
Interleukin-1
Interleukin-6
Adrenal Cortex Hormones
Macrophage Activation Syndrome
Thrombocytosis
Splenomegaly
Leukocytosis
Biological Factors
Child Care
Exanthema
Methotrexate
Anemia
Immune System
Fever
Tumor Necrosis Factor-alpha
Macrophages
Clinical Trials
Cytokines

Cite this

Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis. / Correll, Colleen K; Binstadt, Bryce A.

In: Pediatric Research, Vol. 75, No. 1-2, 01.01.2014, p. 176-183.

Research output: Contribution to journalReview article

@article{09541babe10440ed8b5ce12170729509,
title = "Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis",
abstract = "Systemic juvenile idiopathic arthritis (s-JIA) is clinically distinct from other types of JIA. It is typified by extraarticular features such as quotidian fevers, rash, splenomegaly, lymphadenopathy, laboratory abnormalities (including leukocytosis, thrombocytosis, anemia, hyperferritinemia, and elevated inflammatory markers), and a close association with the macrophage activation syndrome. Recent investigations have highlighted dysregulation of the innate immune system as the critical pathogenic driver of s-JIA. Key innate immune mediators of s-JIA are the macrophage-derived cytokines interleukin-1 (IL-1) and IL-6. Increased understanding of the roles of IL-1 and IL-6 in the pathogenesis of s-JIA has led to major changes in therapeutic options. Until recently, the most commonly used medications included corticosteroids, methotrexate, and tumor necrosis factor (TNF) inhibitors, which are incompletely effective in most cases. Newer biologic agents targeting IL-1 and IL-6 have proven very effective in treating s-JIA and in minimizing corticosteroid exposure. Here we review recent advances in the understanding of the pathogenesis of s-JIA and the recent clinical trials that have revolutionized the care of children with s-JIA.",
author = "Correll, {Colleen K} and Binstadt, {Bryce A}",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/pr.2013.187",
language = "English (US)",
volume = "75",
pages = "176--183",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "1-2",

}

TY - JOUR

T1 - Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis

AU - Correll, Colleen K

AU - Binstadt, Bryce A

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Systemic juvenile idiopathic arthritis (s-JIA) is clinically distinct from other types of JIA. It is typified by extraarticular features such as quotidian fevers, rash, splenomegaly, lymphadenopathy, laboratory abnormalities (including leukocytosis, thrombocytosis, anemia, hyperferritinemia, and elevated inflammatory markers), and a close association with the macrophage activation syndrome. Recent investigations have highlighted dysregulation of the innate immune system as the critical pathogenic driver of s-JIA. Key innate immune mediators of s-JIA are the macrophage-derived cytokines interleukin-1 (IL-1) and IL-6. Increased understanding of the roles of IL-1 and IL-6 in the pathogenesis of s-JIA has led to major changes in therapeutic options. Until recently, the most commonly used medications included corticosteroids, methotrexate, and tumor necrosis factor (TNF) inhibitors, which are incompletely effective in most cases. Newer biologic agents targeting IL-1 and IL-6 have proven very effective in treating s-JIA and in minimizing corticosteroid exposure. Here we review recent advances in the understanding of the pathogenesis of s-JIA and the recent clinical trials that have revolutionized the care of children with s-JIA.

AB - Systemic juvenile idiopathic arthritis (s-JIA) is clinically distinct from other types of JIA. It is typified by extraarticular features such as quotidian fevers, rash, splenomegaly, lymphadenopathy, laboratory abnormalities (including leukocytosis, thrombocytosis, anemia, hyperferritinemia, and elevated inflammatory markers), and a close association with the macrophage activation syndrome. Recent investigations have highlighted dysregulation of the innate immune system as the critical pathogenic driver of s-JIA. Key innate immune mediators of s-JIA are the macrophage-derived cytokines interleukin-1 (IL-1) and IL-6. Increased understanding of the roles of IL-1 and IL-6 in the pathogenesis of s-JIA has led to major changes in therapeutic options. Until recently, the most commonly used medications included corticosteroids, methotrexate, and tumor necrosis factor (TNF) inhibitors, which are incompletely effective in most cases. Newer biologic agents targeting IL-1 and IL-6 have proven very effective in treating s-JIA and in minimizing corticosteroid exposure. Here we review recent advances in the understanding of the pathogenesis of s-JIA and the recent clinical trials that have revolutionized the care of children with s-JIA.

UR - http://www.scopus.com/inward/record.url?scp=84900431110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900431110&partnerID=8YFLogxK

U2 - 10.1038/pr.2013.187

DO - 10.1038/pr.2013.187

M3 - Review article

C2 - 24213625

AN - SCOPUS:84900431110

VL - 75

SP - 176

EP - 183

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 1-2

ER -